|Bid||2.90 x 3400|
|Ask||3.35 x 1000|
|Day's range||2.95 - 3.03|
|52-week range||1.24 - 6.06|
|PE ratio (TTM)||N/A|
|Earnings date||18 May 2017 - 19 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.00|
Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Celsion Corporation’s (NASDAQ:CLSN) track record on a highRead More...
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.